There is a line of credit with an institutional investor already in place.
We have already seen signs at lower dose levels that we may be seeing as the first CarT drug that can target a solid cancer tumour.
We have very good previous data from the NK drug in trial. And thats the trial that is of no cost to CHM.
PH and his family own nearly 25% of the company. This is leveraged by security over a large part of his IMU holding. He has a lot of skin in this company.
Still high risk. But huge upside potential here from this very low market cap and SOI. Isn't this the kind of investment that you look for at this end of the market? To be concerned about CRs at this point in the companies development would tend to suggest that this end of the market isn't for you.
CHM Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)